These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30061050)

  • 1. Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective.
    Saito S; Lasky JA; Hagiwara K; Kondoh Y
    Respir Investig; 2018 Sep; 56(5):375-383. PubMed ID: 30061050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences.
    Natsuizaka M; Chiba H; Kuronuma K; Otsuka M; Kudo K; Mori M; Bando M; Sugiyama Y; Takahashi H
    Am J Respir Crit Care Med; 2014 Oct; 190(7):773-9. PubMed ID: 25162152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.
    Miyashita K; Kono M; Saito G; Koyanagi Y; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Nakamura Y; Suda T; Nakamura H
    Clin Respir J; 2021 Mar; 15(3):336-344. PubMed ID: 33197284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients.
    Azuma A; Hagiwara K; Kudoh S
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1397-8; author reply 1398. PubMed ID: 18522953
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical features of acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: Comparison with idiopathic pulmonary fibrosis.
    Otsuka J; Yoshizawa S; Kudo K; Osoreda H; Ishimatsu A; Taguchi K; Moriwaki A; Wakamatsu K; Iwanaga T; Yoshida M
    Respir Med; 2022; 200():106898. PubMed ID: 35696743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation.
    Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Fujitaka K; Hamada H; Hattori N
    Respir Investig; 2022 Jul; 60(4):531-542. PubMed ID: 35504814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Interstitial Lung Disease-Gender-Age-Physiology Index Can Predict the Prognosis in Surgically Resected Patients with Interstitial Lung Disease and Concomitant Lung Cancer.
    Ueno F; Kitaguchi Y; Shiina T; Asaka S; Yasuo M; Wada Y; Kinjo T; Yoshizawa A; Hanaoka M
    Respiration; 2020; 99(1):9-18. PubMed ID: 31554007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
    Kudoh S; Kato H; Nishiwaki Y; Fukuoka M; Nakata K; Ichinose Y; Tsuboi M; Yokota S; Nakagawa K; Suga M; ; Jiang H; Itoh Y; Armour A; Watkins C; Higenbottam T; Nyberg F
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1348-57. PubMed ID: 18337594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome.
    Okuda R; Hagiwara E; Katano T; Ikeda S; Sekine A; Kitamura H; Baba T; Okudela K; Ohashi K; Ogura T
    Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(1):39-46. PubMed ID: 32476935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of bronchoalveolar lavage cellular analysis in patients with acute exacerbation of interstitial lung disease.
    Kono M; Miyashita K; Hirama R; Oshima Y; Takeda K; Mochizuka Y; Tsutsumi A; Miwa H; Miki Y; Hashimoto D; Suda T; Nakamura H
    Respir Med; 2021 Sep; 186():106534. PubMed ID: 34260978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
    Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
    Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute exacerbation in antineutrophil cytoplasmic antibody-associated interstitial lung disease: Clinical features and risk factors.
    Otsuka J; Yoshizawa S; Ikematsu Y; Kudo K; Osoreda H; Ishimatsu A; Taguchi K; Moriwaki A; Wakamatsu K; Iwanaga T; Yoshida M
    Respir Med; 2022 Nov; 203():106992. PubMed ID: 36252462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study.
    Cao M; Sheng J; Qiu X; Wang D; Wang D; Wang Y; Xiao Y; Cai H
    BMC Pulm Med; 2019 Nov; 19(1):215. PubMed ID: 31727051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.
    Naito Y; Tsuchiya S; Ishihara S; Minato K; Shitara Y; Takise A; Suga T; Mogi A; Yamabe K; Saito R
    Am J Clin Oncol; 2008 Aug; 31(4):340-4. PubMed ID: 18845992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
    Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
    J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
    Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
    J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease.
    Ishikawa G; Acquah SO; Salvatore M; Padilla ML
    Respir Med; 2017 Jul; 128():78-84. PubMed ID: 28610674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and outcome of acute exacerbation in connective tissue disease-associated interstitial lung disease: A single-center study from India.
    Singh P; Thakur B; Mohapatra AK; Padhan P
    Int J Rheum Dis; 2019 Sep; 22(9):1741-1745. PubMed ID: 31328423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C
    Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival.
    Kanaji N; Tadokoro A; Kita N; Murota M; Ishii T; Takagi T; Watanabe N; Tojo Y; Harada S; Hasui Y; Kadowaki N; Bandoh S
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1855-65. PubMed ID: 27350261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.